Now Enrolling: The Canopy ADHD Study

A clinical study using an investigational drug for core symptoms of Attention-deficit/Hyperactivity Disorder

We are currently looking for participants ages 6-17 with Attention-deficit/Hyperactivity Disorder (ADHD) for an open-label clinical trial involving an investigational drug. The purpose of this study is to evaluate the long-term safety and tolerability of the study drug, Centanafadine, for the treatment of children and adolescents experiencing ADHD symptoms, such as hyperactivity, inattentiveness and impulsivity.

STUDY SNAPSHOT:
- Study Duration: 52 weeks (with option to continue up to 136 weeks)
- Total Study Visits: 17 visits (all in person) + 1 phone call for follow-up
- If continuing past the minimum 52 weeks, there will be an in-office visit that takes place every 12-weeks

ELIGIBILITY REQUIREMENTS INCLUDE:
- Individuals ages 6-17
- Cannot have an ASD diagnosis
- Must have an ADHD diagnosis
- Must weigh at least 28.7 lbs

Learn more at autismcenter.org/research

To learn more or enroll, contact SARRC’s research team at: 480.701.3681 ZMerritt@autismcenter.org